TRIlogy-5: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
Full Title
Protocol 79635322MMY3002: A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
Study Treatment
Treatment is randomized between BCMAxGPRC5DxCD3 trispecific antibody JNJ-79635322 and teclistamab.
Eligibility/Info
Multiple myeloma that has been treated with 1-3 prior lines of therapy including an anti-CD38 antibody and lenalidomide.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
Locations
Port Jefferson Station Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.